Unravel Biosciences

Our mission: bring effective drugs to patients in need

PROBLEM:
>90% of drugs fail in the clinic, mostly because their targets are ineffective

OUR SOLUTION:
Drug-driven discovery bridges target discovery with clinical efficacy

HOW WE DO IT:

Unravel combines network-based computational prediction, patient transcriptomic information, and a first-in-class unbiased Xenopus platform to decode, model, and develop new therapeutics for complex diseases.

Pipeline & Discovery

RVL001: a promising proprietary formulation targeting Rett Syndrome arising out of Unravel’s target-agnostic approach
RVL002: a new small molecule with potential applications in CNS, cancer, and metabolic diseases discovered from 17 drug targets of RVL001.
Drug and target discovery: X-linked dystonia Parkinsonism
Biomarkers for NAFLD/NASH patient stratification

We can't do this alone.

We are committed to getting patients effective drugs the fastest way possible. We partner with companies, foundations, and researchers to amplify their strengths and datasets through cost-effective decision-making in the areas of target discovery, mechanism identification, drug optimization, and patient stratification for small molecules and biologics.

decoding complexity

Our mission: bring effective drugs to patients in need

PROBLEM:​>90% of drugs fail in the clinic, mostly because their targets are ineffective

OUR SOLUTION:​Drug-driven discovery bridges target discovery with clinical efficacy

Pipeline & Discovery

We can't do this alone.

PROBLEM:
>90% of drugs fail in the clinic, mostly because their targets are ineffective

OUR SOLUTION:
Drug-driven discovery bridges target discovery with clinical efficacy